News

Jerusalem, Israel, January 24, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has filed infringement complaints against a number of finished dose companies which manufacture sertraline hydrochloride, AB rated to Zoloft®, and their active pharmaceutical ingredient suppliers. Teva filed the complaints in the United States District Courts of New Jersey, Delaware, Southern District New York, and Maryland for infringement of its U.S. Patents Nos. 6,600,073 (expiring June 2020), 6,500,987 (expiring November 2019), 6,495,721 (expiring May 2020) and 6,897,340 (expiri Read More »

Jerusalem, Israel, March 5, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has reached an agreement with Biovail Corporation regarding Bupropion Hydrochloride Extended-Release Tablets ("Bupropion HCl ER tablets"), the generic version of the antidepressant Wellbutrin XL® Tablets, for the United States market. The agreement, following U.S. Federal Trade Commission review, resolves litigation between Teva's supplier of the 300 mg product, IMPAX Laboratories, Inc. (NASDAQ:IPXL) and Biovail involving a patent which expires in 2018. The agreement also rel Read More »

Jerusalem, Israel, March 21, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. District Court for the District of New Jersey has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pfizer's Celebrex® (Celecoxib) Capsules, 100 mg, 200 mg, and 400 mg, holding the three patents at issue valid and enforceable. Teva plans to appeal this decision.Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading gene Read More »

Jerusalem, Israel, May 11, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA)announced today that the U.S. District Court for the Southern District of New York has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Eisai's acid pump inhibitor Aciphex® (Rabeprazole Sodium) Tablets, 20 mg. The Court found Eisai's U.S. Patent No. 5,045,552 enforceable. Teva intends to appeal this decision immediately as well as the Court's decision granting to Eisai Summary Judgment of validity.The FDA has already granted final ap Read More »

Jerusalem, Israel, June 12, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. District Court for the District of New Jersey has vacated a temporary restraining order in effect since May 23, 2007 and denied a motion filed by Novartis for a preliminary injunction related to Teva's amlodipine besylate/ benazepril products, AB rated to Novartis' Lotrel®. In reaching its opinion, the court found that Novartis was not likely to succeed on its allegations of infringement. Teva intends to resume commercial shipments of its amlodipine besylate/ benazepril products i Read More »

Jerusalem, Israel, September 5, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) Announced today that further to its press release dated August 24, 2007, the U.S. District Court For the District of New Jersey has denied a motion filed by Novartis for a preliminary Injunction related to Teva's Famciclovir Tablets, AB-rated to Novartis' Famvir®. Teva's Abbreviated New Drug Application (ANDA) to market its Famciclovir Tablets, 125 mg, 250 mg and 500 mg has already been granted final approval by the U.S. Food and Drug Administration (FDA). The brand product had annual sales of approximatel Read More »

Jerusalem, Israel, September 6, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that further to its press release dated August 2, 2007, the U.S. District Court for the District of New Jersey has denied a motion filed by Wyeth and Altana for a preliminary injunction related to Teva's Pantoprazole Sodium Delayed Release (DR) Tablets, AB-rated to Wyeth's Protonix® DR Tablets. Teva intends to complete a thorough analysis of today's decision before deciding upon its next course of action.Teva's Abbreviated New Drug Application (ANDA) to market its Pantoprazole Tablets, 20 m Read More »

Jerusalem, Israel, September 8, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that further to its press release dated September 7, 2007, it has received notice that the United States Court of Appeals for the Federal Circuit has issued an order temporarily enjoining the Company from further sales of generic Famciclovir Tablets, AB-rated to Novartis' Famvir® Tablets. The injunction will remain in place pending consideration of Novartis' emergency motion for a stay pending appeal. Teva's response to Novartis' emergency motion is due Tuesday, September 11, 2007.Teva Phar Read More »

Jerusalem, Israel, September 21, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the United States Court of Appeals for the Federal Circuit has reversed and remanded an August 2005 summary judgment decision by the U.S. District Court for the District of New Jersey with regards to Pfizer Inc.'s U.S. Patent No. 6,054,482. The District Court had granted summary judgment in Teva's favor on the issue of non-infringement with regard to the patent, which is otherwise set to expire in 2017. The Court of Appeals affirmed the claim construction, but found that there were f Read More »

Jerusalem, Israel, September 27, 2007 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the District Court case has been settled on terms that are confidential allowing Teva by license to enter the U.S. market with its generic versions of Avandia® (Rosiglitazone Maleate), Avandamet® (Rosiglitazone Maleate/Metformin HCl) and Avandaryl® (Rosiglitazone Maleate/Glimepiride) oral tablets late in the first quarter, 2012.About TevaTeva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), headquartered in Israel,is among the top 20 pharmaceutical companies in the world and is the lea Read More »